RenJi Hospital

Other

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

242

Clinical Trials↗

All sponsored trials (all statuses)

Pipeline

Pipeline Snapshot

By Phase

46 drugs in development

Phase 35

Phase 28

Phase 17

Preclinical33

By Therapeutic Area

top 6

Oncology

2451%

Metabolic & Endocrine

36%

Immunology

24%

Nephrology

24%

Gastroenterology

12%

Respiratory

12%

R&D Momentum

80/100

Pipeline Velocity

41/100

Trial Completion Rate

92/100

Pipeline Concentration

35/100

Pipeline Freshness

52/100

Strategic Signals

↗Active in Gastroenterology but thin pipeline — potential licensing opportunity

Activity

Recent Activity

Last 14 days

Sep 18, 2026

Completed

Physician-initiated, Prospective, Multi-center，Observational Study: The Efficacy of Endovascular Treatment in Femoropopliteal Occlusive Disease (FPOD) With TransAtlantic InterSociety Consensus (TASC) C and D Lesions

Sep 17, 2026

Active, not recruiting

A Multicenter, Single-Arm, Phase II Study Evaluating the Efficacy and Safety of Fruquintinib Combined With Serplulimab as First-Line Treatment in Patients With Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma

Sep 11, 2026

Recruiting

Safety and Efficacy of Ventricular Irrigation for Ventriculitis: a Randomized Controlled Trial

Sep 11, 2026

Completed

A Prospective, Single Arm Clinical Study to Evaluate Efficacy and Safety of Lenvatinib Combined With Tislelizumab in the First Line Treatment of Patients With Locally Advanced or Metastastic Fumarate Hydratase Deficient Renal Cell Carcinoma

Earlier

Sep 3, 2026TrialPROfunda Femoris Vein Thrombosis Evaluation and Clearance to Improve Outcomes of Endovascular Treatment for Acute Iliofemoral Deep Vein Thrombosis: a Multicenter Randomized Controlled Study (The PROTECT Study)

Aug 19, 2026TrialRetlirafusp Alfa Combined With Definitive Concurrent Chemoradiotherapy in Local Advanced Unresectable Esophageal Squamous Cell Cancer

Aug 19, 2026TrialCorrelation of the Cancer and Aging Research Group (CARG) Chemotherapy Toxicity Risk Scores and Unplanned Hospitalizations in Older Cancer Patients--A Multi-center Prospective Cohort Study

Aug 14, 2026TrialA Multi-center, Randomized, Controlled Trial to Evaluate the Efficacy and Safety of Long-term Mild Hypothermia in Adult Patients With Severe Traumatic Brain Injury

3 more events

Aug 14, 2026TrialThe Early Intervention of Fascia Iliaca Compartment Block (FICB) as Pain Management for Elderly Patients With Hip Fracture to Improve Postoperative Rehabilitation: A Prospective Randomized Controlled Study

Aug 13, 2026TrialLow-dose Droperidol for Prevention of Postoperative Delirium in Elderly Patients After Non-cardiac Surgery: A Randomized, Double-blind, Placebo-controlled Trial

Aug 12, 2026TrialA Trial to Evaluate the Effect of Applying Leukapheresis to Enrich CTCs in Patients With Metastatic Prostate Cancer

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Pipeline

Drug Pipeline

Therapeutic Area

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Cardiovascular(1 drug)

—

Cardiovascular(1 drug)

Gastroenterology(1 drug)

—

Gastroenterology(1 drug)

Immunology(2 drugs)

—

Immunology(2 drugs)

Metabolic & Endocrine(3 drugs)

—

Metabolic & Endocrine(3 drugs)

Nephrology(2 drugs)

—

Nephrology(2 drugs)

Oncology(24 drugs)

—

Oncology(24 drugs)

Respiratory(1 drug)

—

Respiratory(1 drug)

Unknown / Other(13 drugs)

—

Unknown / Other(13 drugs)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)